I think the market forgets the trouble Xtandi will have growing in the face of generic competition of Zytiga. Its patent will expire in 2016/17. So just as Xtandi sales are ramping up say 2014/15 then there will be the realization that generic competition is upon them. With no pipeline they have nothing else pulling them forward. This has been widely forgotten by the market. In fact by the time Xtandi is approved for front line therapy, which would really ramp up sales it will see generic competition a year or two later.